DGAP-News

Evotec achieves further milestones in TargetAD collaboration with Janssen

DGAP-News: Evotec AG / Key word(s): Alliance
Evotec achieves further milestones in TargetAD collaboration with
Janssen

15.01.2015 / 07:28

---------------------------------------------------------------------

Hamburg, Germany - 15 January 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced the achievement of several
small, but very important milestones in its TargetAD collaboration with
Janssen Pharmaceuticals, Inc. ("Janssen") for the identification and
selection of novel targets from Evotec's TargetAD database and for the
transition of targets into the drug discovery process. These milestones
were reached in 2014 which will be recognised in the financial year 2014.

These selections were achieved under the agreement between Evotec and
Janssen, facilitated by Johnson & Johnson Innovation LLC, signed in
November 2013. Under the terms of the agreement, Janssen and Evotec
continue to collaborate to develop new drugs for Alzheimer's disease.

Janssen has the option to internalize selected targets and therapeutic
candidates and progress them into pre-clinical and clinical development.
Janssen funds target drug discovery research via a combination of defined
research payments and progress-related milestones.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "It was
only in July 2014 that we announced the achievement of the first milestones
in our TargetAD collaboration together with Janssen. The recent achievement
of two further milestones further validates our approach and is a testament
to a highly productive collaboration. I would like to congratulate the
teams from both companies on the excellent progress and wish them continued
success moving forward in their quest for innovative Alzheimer's disease
therapies."

ABOUT EVOTEC'S TARGETAD DATABASE
The TargetAD database is a customized system providing unique information
on the link between molecular and cellular changes in brain tissue with AD
progression. This database was set up in a multi-year research programme,
applying histological, cellular and in vivo target validation procedures.
The database provides a strong foundation for systematic collaborative
target validation and compound discovery programmes.

ABOUT ALZHEIMER'S DISEASE
Alzheimer's disease ("AD") is an irreversible, progressive brain disease
and the main cause for dementia. It slowly destroys brain cells and nerves
and thus disrupts the transmission in the brain, particularly those
responsible for storing memories. In the course of AD, the brain shrinks as